News from volitionrx ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 05, 2019, 08:30 ET VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it was awarded $820,000 (€740,000 Euros) and Gyros Protein Technologies...


Dec 03, 2019, 08:30 ET VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its latest proof of concept study. A single pre-clinical Nu.Q™...


Nov 13, 2019, 03:54 ET VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September...


Nov 12, 2019, 16:10 ET VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September...


Nov 07, 2019, 08:30 ET VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update

VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced it will host a conference call on Wednesday, November 13 at 8:30 a.m. Eastern...


Oct 29, 2019, 08:30 ET Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the confirmation of a further $500,000 non-dilutive funding in the form of a...


Oct 25, 2019, 12:00 ET Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") announced today that it (through its subsidiaries) has executed binding agreements contemplated ...


Oct 18, 2019, 08:30 ET Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred...


Oct 09, 2019, 16:05 ET Volition Appoints Dr. Phillip Barnes to Board of Directors

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the appointment of Dr. Phillip Barnes to the Company's Board of Directors as a...


Sep 17, 2019, 08:35 ET Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.QTM Capture development program: the ability...


Aug 12, 2019, 16:05 ET VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30,...


Aug 08, 2019, 08:30 ET Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics...


Aug 07, 2019, 08:45 ET VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update

VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Tuesday, August 13 at 8:30 a.m. Eastern time to discuss...


Jul 24, 2019, 16:05 ET Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor...


Jul 18, 2019, 08:30 ET VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with...


Jul 10, 2019, 08:30 ET VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a...


May 08, 2019, 16:05 ET VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31,...


May 07, 2019, 08:30 ET VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of ...


May 06, 2019, 16:05 ET VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Thursday, May 9 at 8:30 a.m. Eastern time to discuss its...


Apr 09, 2019, 17:17 ET VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties...


Apr 09, 2019, 08:30 ET VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned...


Apr 03, 2019, 08:30 ET VolitionRx Limited Extends Clinical Trial Program in Lung Cancer

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of ...


Mar 28, 2019, 10:48 ET VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") with Shanghai Fosun Long March...


Mar 25, 2019, 08:40 ET VolitionRx Limited to Present at Conferences in March & April 2019

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell, is...


Mar 15, 2019, 08:30 ET VolitionRx Limited to Present at Conferences in the U.S. Next Week

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Mr. Cameron Reynolds, is scheduled to present ...